Domain-Specific LLMs 2026: Vertical AI for Law, Finance, Healthcare

Q: What is a domain-specific LLM and why do regulated industries need one?

A domain-specific LLM is a system — usually a foundation model combined with a curated authoritative corpus, domain-specific reasoning patterns, and vertical evaluation discipline — designed to operate reliably inside a specialised, knowledge-dense field such as law, finance, or healthcare. Regulated industries need this approach because generic foundation models trained on the open internet have structural failure modes in these verticals: they hallucinate case citations (the famous Mata v. Avianca incident in legal AI), misinterpret financial filings against incorrect materiality thresholds, and produce clinical recommendations that contradict current evidence-based guidelines. The training data is unrepresentative, the specialised vocabulary is fragmented by generic tokenisers, and the domain-specific reasoning chains (legal precedent reasoning, financial ratio analysis, clinical differential diagnosis) are not reliably reproduced. Domain-specific systems address these gaps with curated knowledge, citation-required output, and evaluation against expert-labelled domain test sets.

Q: Should I fine-tune a model or use domain RAG for vertical AI?

Use domain RAG when the knowledge changes frequently and citation traceability is critical (most legal, financial, and healthcare use cases fall here). The model stays generic, the knowledge layer becomes the differentiator, and updates land daily without retraining. Add fine-tuning when the domain reasoning style itself is the differentiator and prompt engineering cannot reliably elicit it from a generic model — for example, when you need outputs structured like a legal memo, a financial analyst report, or a clinical note that a practitioner immediately recognises as authentic. The 2026 leaders in vertical AI use a combination: fine-tune for reasoning style, RAG for current authoritative facts, with citation discipline gating every output. Pure fine-tuning on facts is rarely the right answer because facts go stale; pure prompt engineering on a generic model rarely clears the quality bar in regulated verticals. The third option — a smaller distilled domain-specific model — is increasingly common when latency, cost, or data residency constraints rule out frontier models.

Q: How do you deploy LLMs in healthcare while staying HIPAA-compliant?

HIPAA compliance for healthcare LLMs has two viable deployment patterns. The first is private deployment of models on infrastructure you control — typically a fine-tuned open-source model (Llama 3, Mistral, or a healthcare-specific variant) running in your own VPC, with no third-party API calls outside your trust boundary, encryption in transit and at rest, comprehensive audit logging meeting HIPAA requirements, and access controls integrated with your existing identity infrastructure. The second is using cloud LLM services covered by Business Associate Agreements — Microsoft Azure OpenAI Service in HIPAA-eligible configuration, AWS Bedrock in HIPAA-eligible configuration, or specialised healthcare AI vendors with HIPAA-compliant SaaS offerings. Either way, no PHI can leave the BAA-covered surface, no PHI can land in third-party observability tools without scrubbing, and the architecture must support the right to access and erasure that the underlying compliance regime requires. The deployment topology is the constraint that shapes every other architectural decision; choose it before you choose the model or the framework.

Q: What are the leading vertical AI vendors in law, finance, and healthcare?

Legal: Harvey (used by Allen & Overy, PwC, and many large firms), Robin AI (contract review and drafting), Casetext / Thomson Reuters CoCounsel (legal research and memo drafting), and Lexis+ AI (LexisNexis legal research). Financial research and analysis: AlphaSense (search and intelligence over filings, transcripts, and broker research), Hebbia (deep document research for institutional finance), Bloomberg Terminal AI features (derived from BloombergGPT), and FactSet AI integrations. Healthcare clinical workflows: Hippocratic AI (clinical patient-facing applications), Abridge (clinical documentation from patient encounters), Nabla (consultation summarisation), and Microsoft / Nuance DAX (ambient clinical documentation). Plus a long tail of specialised vendors covering patent law, tax accounting, clinical trial design, regulatory monitoring, and dozens of other niches. The buy-vs-build decision in 2026 increasingly favours buying or licensing one of these platforms for the foundational capability and investing internally in workflow integration, proprietary knowledge contribution, and evaluation discipline.

Q: Why is faithfulness more important than accuracy for vertical AI?

In regulated verticals the practitioner — the lawyer, analyst, or clinician — is ultimately responsible for the decision and must verify the system's output against an authoritative source. A faithful but partially incomplete answer with accurate citations is more valuable than a confident comprehensive answer that hallucinates a citation, because the practitioner can verify the first and cannot trust the second. Faithfulness measures whether the cited source actually supports the claim the system makes; accuracy measures whether the claim is correct in the abstract. A system that scores 95 percent on accuracy but 70 percent on faithfulness is dangerous because 30 percent of its citations do not support what it asserts, and the practitioner has no reliable way to know which 30 percent. A system that scores 85 percent on accuracy but 98 percent on faithfulness is trustworthy because the practitioner can verify the citation and accept or reject the output on that basis. The 2026 vertical AI leaders measure faithfulness explicitly using LLM-as-judge evaluation plus expert review on stratified samples and gate deployment on faithfulness thresholds.

Q: What evaluation discipline does production vertical AI require?

Generic LLM benchmarks (MMLU, HellaSwag, HumanEval) are useless for vertical evaluation — they tell you nothing about whether a system can reliably interpret a 10-K disclosure, identify a relevant precedent in the controlling jurisdiction, or recognise a contraindication in a complex medication list. Production vertical AI requires three layers of evaluation. First, a custom domain test set of thousands of expert-labelled cases capturing the actual judgements the system needs to make, the actual sources it needs to cite, and the actual reasoning it needs to follow — this is core IP and is treated as such. Second, automated metrics including faithfulness scoring (does the cited source support the claim), accuracy on the domain test set, citation precision, and refusal-rate calibration on out-of-scope queries. Third, continuous expert review programmes — panels of practising lawyers, analysts, or physicians who review samples of system output and label quality issues for training feedback. The third layer captures the long-tail edge cases that drive practitioner trust and is what separates systems that practitioners trust from systems that practitioners politely tolerate.

Q: How does FINRA and SEC oversight shape financial AI architecture?

Financial communications fall under recordkeeping rules — SEC Rule 17a-4 and FINRA Rule 4511 — that require retention of all business communications, including AI-generated ones, in immutable WORM-compliant form for years. Investment recommendations require disclosure of conflicts and the basis for the recommendation. Personalised marketing has restrictions on what can be said and to whom. The architectural consequences are: comprehensive logging of every model interaction (user, model version, prompt, response, source citations) into immutable storage; clear separation in the system between general information and investment advice with appropriate disclosures; supervisory review workflows that meet the firm's compliance posture; and time-aware retrieval so the system never produces output dependent on information not available at the relevant time. Several prominent financial firms have been fined for AI-generated communications that did not meet these requirements; the lesson is that AI does not exempt the firm from rules that already apply to communication, and the architecture must encode the compliance posture rather than treating compliance as an afterthought.

Q: When does it make sense to build a vertical AI system in-house rather than buy?

Pure build is the right answer in narrow circumstances. When the use case is highly specific and not well-served by off-the-shelf vertical platforms (a tax-credit qualification system for a particular country's regime, a clinical pathway for a single rare-disease specialty, a regulatory monitoring system for a niche jurisdiction). When the proprietary corpus is genuinely the differentiator and you would not entrust it to a third-party vendor even under a strong agreement. When the organisation has the in-house expertise to operate vertical AI infrastructure: domain experts, ML engineers, regulatory counsel, evaluation engineers, and the operational discipline to run continuous expert review. When data residency or sovereignty requirements rule out the leading platforms. The minimum viable team is meaningfully larger than typical AI projects and the timeline is measured in quarters not weeks. The trade-off is a system the organisation owns end-to-end versus a platform dependency. For most enterprises in regulated verticals, the right answer in 2026 is the middle path — buy the platform, build the workflow integration and proprietary knowledge layer, partner with the platform vendor on corpus contributions and evaluation feedback. Pure build is the exception, not the default.